Tenon Medical announced full early repayment of its $5.16 million senior convertible notes, removing a major dilution overhang ahead of September maturity. The move strengthens the balance sheet while preserving flexibility to push Catamaran SI Joint Fusion system commercialization, supported by Q2 revenue of $1.28 million and a 64% gross margin. The catalyst could drive a near-term stock rebound, though longer-term upside depends on continued adoption and profitability.
Tenon Medical disclosed a private placement expected to raise roughly $3 million by selling 597,610 common shares (or pre-funded equivalents) and issuing warrants for up to 1,058,517 shares at an effective price near $5.02. The offering should close around August 31, 2026, with WallachBeth Capital as exclusive placement agent; proceeds will support ongoing sacro-pelvic disorder initiatives amid SI joint growth.
